JP2020520910A - 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物 - Google Patents

固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物 Download PDF

Info

Publication number
JP2020520910A
JP2020520910A JP2019563379A JP2019563379A JP2020520910A JP 2020520910 A JP2020520910 A JP 2020520910A JP 2019563379 A JP2019563379 A JP 2019563379A JP 2019563379 A JP2019563379 A JP 2019563379A JP 2020520910 A JP2020520910 A JP 2020520910A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
aluminum
amino
pharmaceutically acceptable
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019563379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520910A5 (https=
Inventor
クーク，マイケル
カシバートラ，シャイラジャ
ティー． ミラー，アンドリュー
ティー． ミラー，アンドリュー
ヤオ−シアン ウー，トム
ヤオ−シアン ウー，トム
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020520910A publication Critical patent/JP2020520910A/ja
Publication of JP2020520910A5 publication Critical patent/JP2020520910A5/ja
Priority to JP2023060740A priority Critical patent/JP2023093524A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019563379A 2017-05-19 2018-05-17 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物 Withdrawn JP2020520910A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060740A JP2023093524A (ja) 2017-05-19 2023-04-04 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508474P 2017-05-19 2017-05-19
US62/508,474 2017-05-19
PCT/IB2018/053481 WO2018211453A1 (en) 2017-05-19 2018-05-17 Compositions comprising naphthyridine derivatives and aluminium adjuvant for use in treating solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060740A Division JP2023093524A (ja) 2017-05-19 2023-04-04 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物

Publications (2)

Publication Number Publication Date
JP2020520910A true JP2020520910A (ja) 2020-07-16
JP2020520910A5 JP2020520910A5 (https=) 2021-07-26

Family

ID=62597814

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019563379A Withdrawn JP2020520910A (ja) 2017-05-19 2018-05-17 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物
JP2023060740A Pending JP2023093524A (ja) 2017-05-19 2023-04-04 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060740A Pending JP2023093524A (ja) 2017-05-19 2023-04-04 固形腫瘍の治療において使用するための、ナフチリジン誘導体及びアルミニウムアジュバントを含む組成物

Country Status (13)

Country Link
US (2) US11752162B2 (https=)
EP (1) EP3624806A1 (https=)
JP (2) JP2020520910A (https=)
KR (1) KR20200007040A (https=)
CN (2) CN110636848A (https=)
AR (1) AR111760A1 (https=)
AU (2) AU2018268420B2 (https=)
BR (1) BR112019024260A2 (https=)
CA (1) CA3062609A1 (https=)
CL (1) CL2019003293A1 (https=)
MX (2) MX2019013720A (https=)
TW (1) TW201900166A (https=)
WO (1) WO2018211453A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523705A (ja) * 2010-03-31 2013-06-17 スタビリテック リミテッド ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
JP2013538217A (ja) * 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
JP2014519512A (ja) * 2011-06-10 2014-08-14 アフィリス・アクチェンゲゼルシャフト Ｃｅｔｐ断片
WO2017076873A1 (en) * 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
EP0708772B1 (en) 1993-07-15 2000-08-23 Minnesota Mining And Manufacturing Company IMIDAZO [4,5-c]PYRIDIN-4-AMINES
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
TW200526656A (en) 2003-10-03 2005-08-16 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CN102892786B (zh) 2010-03-11 2016-03-16 Ucb医药有限公司 Pd-1抗体
WO2011130379A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
SG11201400210RA (en) 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
JP6411378B2 (ja) 2013-02-01 2018-10-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
BE1022875B1 (fr) 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
KR102540008B1 (ko) 2014-08-01 2023-06-02 쓰리엠 이노베이티브 프로퍼티즈 캄파니 종양을 치료하기 위한 방법 및 치료적 조합
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523705A (ja) * 2010-03-31 2013-06-17 スタビリテック リミテッド ミョウバンアジュバントおよびミョウバンアジュバント化ワクチンの保存方法
JP2013538217A (ja) * 2010-09-01 2013-10-10 ノバルティス アーゲー 不溶性金属塩への免疫増強物質の吸着
JP2014519512A (ja) * 2011-06-10 2014-08-14 アフィリス・アクチェンゲゼルシャフト Ｃｅｔｐ断片
WO2017076873A1 (en) * 2015-11-03 2017-05-11 Affiris Ag Method for vaccination against a self-antigen in a human patient

Also Published As

Publication number Publication date
CN116473981A (zh) 2023-07-25
AU2018268420A1 (en) 2019-11-21
AU2021203564A1 (en) 2021-07-01
AU2021203564B2 (en) 2023-01-05
WO2018211453A1 (en) 2018-11-22
RU2019141837A3 (https=) 2021-09-10
EP3624806A1 (en) 2020-03-25
TW201900166A (zh) 2019-01-01
CL2019003293A1 (es) 2020-03-13
BR112019024260A2 (pt) 2020-06-09
JP2023093524A (ja) 2023-07-04
MX2023004381A (es) 2023-05-04
CN110636848A (zh) 2019-12-31
US20210154214A1 (en) 2021-05-27
US20240009215A1 (en) 2024-01-11
AU2018268420B2 (en) 2021-07-15
MX2019013720A (es) 2020-01-30
AR111760A1 (es) 2019-08-14
KR20200007040A (ko) 2020-01-21
RU2019141837A (ru) 2021-06-21
CA3062609A1 (en) 2018-11-22
US11752162B2 (en) 2023-09-12

Similar Documents

Publication Publication Date Title
US20240009215A1 (en) Compounds and compositions for treating solid tumors by intratumoral administration
US12383572B2 (en) Administration of an anti-activin-a compound to a subject
RU2743077C2 (ru) Конъюгат анти-trop2 антитело-лекарственное средство
JP2021155431A (ja) ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
KR102082363B1 (ko) 난소암의 치료를 위한 조합 치료
KR20140063825A (ko) 클로스트리듐 디피실의 주요 외독소 tcda 및 tcdb에 대한 중화 항체
JP6951441B2 (ja) Ｍｅｔ抗体薬物複合体
KR20190088571A (ko) 교모세포종의 치료를 위한 조합 요법
TWI771372B (zh) Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案
KR20200083503A (ko) Tim-3 경로와 pd-1 경로의 이중 저해제
JP2022514499A (ja) 抗ｉｌ－２７抗体及びその使用
JP2021518138A (ja) 抗ｉｌ−２７抗体及びその使用
JP2019522658A (ja) 線維症の治療に使用するためのＷｎｔ阻害剤
JP6909220B2 (ja) ヒト抗ｆｇｆｒ４抗体およびソラフェニブの組み合わせ
RU2787157C2 (ru) Композиции, содержащие производные нафтиридина и алюмосодержащее вспомогательное средство, предназначенные для применения в лечении солидных опухолей
WO2022009157A1 (en) Lhc165 and spartalizumab combinations for treating solid tumors
TW201832782A (zh) 包含阿維魯單抗(avelumab)之組合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220818

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230412

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230418

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230421